Biogen Inc. (NASDAQ:BIIB) Shares Sold by National Pension Service

National Pension Service lessened its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 30.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 250,085 shares of the biotechnology company's stock after selling 109,484 shares during the quarter. National Pension Service owned 0.17% of Biogen worth $38,243,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Advisor OS LLC purchased a new stake in Biogen in the fourth quarter valued at approximately $431,000. Illinois Municipal Retirement Fund lifted its stake in Biogen by 24.3% during the 4th quarter. Illinois Municipal Retirement Fund now owns 62,181 shares of the biotechnology company's stock valued at $9,509,000 after acquiring an additional 12,166 shares during the period. Prasad Wealth Partners LLC purchased a new stake in shares of Biogen in the 4th quarter valued at $222,000. BankPlus Trust Department acquired a new stake in shares of Biogen in the fourth quarter worth $106,000. Finally, Y Intercept Hong Kong Ltd raised its holdings in shares of Biogen by 111.0% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 15,148 shares of the biotechnology company's stock worth $2,316,000 after purchasing an additional 7,970 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of several analyst reports. Royal Bank of Canada cut their price target on Biogen from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Thursday, February 13th. Sanford C. Bernstein started coverage on Biogen in a report on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 price target for the company. BMO Capital Markets cut their target price on shares of Biogen from $156.00 to $139.00 and set a "market perform" rating for the company in a report on Thursday, February 13th. Scotiabank lowered their price target on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a report on Thursday, February 13th. Finally, HC Wainwright dropped their price target on shares of Biogen from $300.00 to $241.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $213.33.

Biogen Trading Up 0.9 %

Shares of NASDAQ BIIB traded up $1.21 during trading on Monday, hitting $141.71. 1,616,469 shares of the company were exchanged, compared to its average volume of 1,471,824. The company has a fifty day moving average price of $144.28 and a 200-day moving average price of $167.83. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The firm has a market capitalization of $20.74 billion, a PE ratio of 12.66, a P/E/G ratio of 1.51 and a beta of -0.08. Biogen Inc. has a 12-month low of $128.51 and a 12-month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, equities research analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.